Skip to main content
Premium Trial:

Request an Annual Quote

NanoMosaic Closes $40.8M Series A Round

NEW YORK – Proteomics firm NanoMosaic said Monday that it has closed a $40.8 million Series A funding round.

The Boston-based company said it will use the funds to build its commercial infrastructure, further its application development efforts, and pursue collaborative diagnostic development programs.

The round was led by RA Capital Management and joined by Insight Partners, Pura Vida Investments, Time BioVentures, and Tiger Gene.

NanoMosaic's proteomics platform, called Tessie, uses arrays of silicon "nanoneedles" that are functionalized with antibodies or other affinity reagents to detect and quantify proteins. The system's measurements are based on changes in resonance that occur when target molecules bind to the functionalized needles, resulting in a change of color. The platform can also detect nucleic acids.

NanoMosaic is targeting Q1 2022 for launch of the system. According to the company, this first-generation system will allow for protein measurements across seven orders of magnitude in up to 384 samples in 20 minutes. It will also allow for protein and nucleic acid measurements on the same chip in a single run.

"NanoMosaic places the future of proteomics in the hands of scientists: fully configurable, simple to run, and ripe for additional application development," Anurag Kondapalli, principal at RA Capital, said in a statement.

"RA Capital, Insight Partners, Pura Vida Investments, and Time BioVentures have been significantly involved with the company and have developed a strong rapport with the NanoMosaic team," said John Boyce, cofounder, interim president, and CEO of NanoMosaic. "The collective effort of the syndicate will enable novel proteomics and multiomics applications that will usher in a new era of diagnostic and therapeutic development initiatives."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.